We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Helper T-Cells Maintain Immune Protection Against HCV

By Biotechdaily staff writers
Posted on 04 Nov 2003
A recent study describes the interaction of CD4+ ("helper”) and CD8+ ("killer”) T lymphocytes during the immune response that develops when an individual is infected by the hepatitis C virus (HCV).

HCV causes liver damage in about 170 million people around the world. More...
To learn how the body defends itself against the virus, investigators at Ohio State University (Columbus, USA) used chimpanzees to study the effect of depleting certain lymphocyte populations from the immune system. They reported in the October 24, 2003, issue of Science that chimpanzees which had become immune to HCV after recovering from the disease lost their immunity when CD4+ lymphocytes were removed by antibody treatment. The virus was able to avoid the CD8+ cells that remained and establish a new infection.

"Our goal is to understand how a person's immune response determines the outcome of the hepatitis C infection,” explained senior author Dr. Christopher M. Walker, professor of pediatrics at the Ohio State University College of Medicine and Public Health. "Approximately 70% of individuals exposed to hepatitis C become lifelong carriers of the virus. The remaining individuals successfully contain the infection and appear to have long-lasting immunity to the virus. Our finding that CD4+ T helper cells are essential for this protection move us one step closer to developing an effective vaccine for hepatitis C.”




Related Links:
Ohio State University

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
POC Immunoassay Analyzer
Procise DX
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.